The argument · idea-019
For prescription use in the home by adults with symptomatic neurogenic; orthostatic hypotension due to primary autonomic failure (Parkinson disease, multiple; system atrophy, or pure autonomic failure) who remain symptomatic despite non-pharmacologic; measures, to apply servo-controlled abdominal compression automatically on assumption of; an upright posture and to release it on return to a seated or recumbent posture, to reduce; orthostatic symptom burden and increase upright standing time.
Chairs disagreeing in writing is the output here, not a
problem to be resolved. A blocks verdict opens an impact review; it does
not kill anything, and no department holds a veto. Killing is Stage 5 arithmetic over verified
claims. converged is not an approval either — the only approval in this repo is a
human's, at Stage 6.
flowchart TD
A11["Assumption, not a fact: adults with…<br><small>A11 · claim 28 · unconfirmed</small>"]
A15["Midodrine and droxidopa are…<br><small>A15 · claim 11 · unconfirmed</small>"]
A20["TAM component 3 of 4 — price per…<br><small>A20 · claim 23 · unconfirmed</small>"]
A42["In a single-arm home-use…<br><small>A42 · claim 99 · unconfirmed</small>"]
A43["A randomized, double-blind…<br><small>A43 · claim 100 · unconfirmed</small>"]
A46["None of the 510(k) clearances under…<br><small>A46 · claim 103 · unconfirmed</small>"]
A51["A posture classifier running on a…<br><small>A51 · claim 108 · unconfirmed</small>"]
A52["A battery-powered pneumatic unit…<br><small>A52 · claim 109 · unconfirmed</small>"]
A53["A bench rig demonstrates that the…<br><small>A53 · claim 110 · unconfirmed</small>"]
A54["An independent recumbency…<br><small>A54 · claim 111 · unconfirmed</small>"]
A57["A wearable unit powered by a…<br><small>A57 · claim 114 · unconfirmed</small>"]
A7["A torso-mounted accelerometer or…<br><small>A7 · claim 48 · unconfirmed</small>"]
d_regulatory["Regulatory<br><small>conditional</small>"]
d_clinical["Clinical & Scientific<br><small>conditional</small>"]
d_market-access["Market Access<br><small>conditional</small>"]
d_technology["Technology & R&D<br><small>conditional</small>"]
d_operations-npi["Operations & NPI<br><small>conditional</small>"]
d_commercial["Commercial<br><small>abstains</small>"]
A11 --> d_clinical
A11 --> d_operations-npi
A11 --> d_commercial
A15 --> d_clinical
A15 --> d_market-access
A15 --> d_commercial
A20 --> d_market-access
A20 --> d_operations-npi
A20 --> d_commercial
A42 --> d_clinical
A42 --> d_market-access
A42 --> d_commercial
A43 --> d_regulatory
A43 --> d_clinical
A43 --> d_market-access
A46 --> d_regulatory
A46 --> d_market-access
A46 --> d_commercial
A51 --> d_regulatory
A51 --> d_clinical
A51 --> d_technology
A52 --> d_clinical
A52 --> d_technology
A52 --> d_operations-npi
A53 --> d_regulatory
A53 --> d_technology
A53 --> d_operations-npi
A54 --> d_regulatory
A54 --> d_clinical
A54 --> d_technology
A57 --> d_technology
A57 --> d_operations-npi
A57 --> d_commercial
A7 --> d_regulatory
A7 --> d_clinical
A7 --> d_technology
class A11,A15,A20,A42,A43,A46,A51,A52,A53,A54,A57,A7,d_regulatory,d_clinical,d_market-access,d_technology,d_operations-npi t2;Each chair answers cold, from its own field, without reading the others' position files. What it states is a verdict, the conditions that would change it, and the requests it raises. A condition bound to a claim is a load-bearing statement, which is why it shows up in the register below.
backs it only if its conditions hold
backs it only if its conditions hold
backs it only if its conditions hold
backs it only if its conditions hold
backs it only if its conditions hold
mechanism: is a system of at least three separately manufactured objects with different service lives: a reusable powered controller (pump, vent valve, pressure… claim 92 · unconfirmedwill not hold a position on the evidence available
will not hold a position on the evidence available
The opportunity is still in its original shape — no pivot has been recorded. That is not the same as being confirmed; it means no failed statement has yet forced a change of shape.
When a registered statement comes back refuted or unconfirmed, an
impact review fires. It has exactly three available outcomes and
check_loop.py refuses a record that invents a fourth. Open one for the reasoning.
data/fda_denovo.csv was absent
on 2026-09-18. Turn 2: it has now been run. The Verifier re-ran six device-name
queries against the 494-record cache on 2026-09-29, and none matched. The connector
reports that as refuted, meaning it found no matching grant. That agrees with claim 3unconfirmed's
absence statement and does not contradict it. The claim stays unconfirmed because the
listing is keyed on names, not indications. The nearest OH-adjacent entries, DEN160044 (an FDA De Novo decision number) and
DEN230076, are a hypotension-prediction algorithm and a BP monitor, not compression
therapy. This matches claim 55verified (Regulatory's name searches). For
claim 103unconfirmed, all six 510(k) summaries are unreadable (pre-1996, HTTP 401/404). The product
codes check out (LHX "Trousers, Anti-Shock"; JOW), but the cleared indications are not on
any record this repo can reach.
hasResults=false. No results are posted. A PubMed scan for the
NCT number since 2018 returned nothing. Clinical's own literature search found no publication
either. The claim is disjunctive, and a scan miss is not an absence, so the Verifier left the
published half open and did not refute it. Nothing supports the claim.
blocks on a
symptom-reduction intended use and to asking for a BP/tolerance-only indication. The only
controlled evidence for the mechanism class would then be single-blind (claim 5verified),
and the symptom claim in intended_use: would lose its nearest precedent.
adoption
returns unverifiable by design, and the Verifier did not substitute a judgment. The
adjacent record points one way. claim 70unconfirmed: 43% never used stockings, and 51% had difficulty
applying them. Claims 71 and 72: views on abdominal compression were mixed, and it was rated
less comfortable than leg compression. Claims 57, 59 and 74 record tolerability at study-day
or four-week elastic-binder exposure only. Nothing measures sustained home wear of a powered
device.
intended_use:. The MSA-P and postural-deformity patients most exposed to supine
hypertension are exactly the ones the classifier is least likely to serve. If venting is
not firmware-independent, no special control can be written at all.
mechanism:'s "supine exposure … zero by
construction" cannot be met by any sensor-triggered system. It asks the front end to
restate it as "bounded, with an independent interlock". That is a chair's engineering
reading, not a failed statement. claim 31unconfirmed is unconfirmed, not refuted, so it is not
acted on as a pivot. What settles it is REQ-0117 If supine exposure to 40 mmHg abdominal… together with REQ-0118 Would FDA review of a De Novo safety case…. If Clinical names a
harmless bound and Regulatory accepts a bounded hazard analysis, the restatement is a
wording change to mechanism: and is recorded as a redesign, under that word. If Clinical
says no bound is harmless in this population, that is a finding, and it routes to trigger T2
below.
data/hcpcs_level_ii.csv was absent, so nothing was looked up in either direction. The
cache landed on 2026-09-28 (October 2026 Level II file). **claim 115unconfirmed's descriptor half has
since been verified against it:** E0650 is "non-segmental home model", E0656 and E0657 are
segmental trunk and chest, every non-segmental appliance is a limb, and no code names the
abdomen. The conclusion half is a PDAC (Pricing, Data Analysis and Coding contractor) coding determination no connector answers. The
Verifier notes a third route the claim omits: E1399, "DME, miscellaneous".
Turn 2 re-run (2026-09-29): the present-tense halves of claims 10 and 40 now verify
against the same file. E0650-E0652, E0655, E0656 and E0657 exist with no termination
date, and so does E1399. Both tags stay unconfirmed for a different reason. For claim 10unconfirmed, the only unchecked part is the negative half, "no device-specific code exists", which
the code-keyed connector cannot search. For claim 40unconfirmed, the unchecked part is the future
CMS act. The Verifier's note says it outright: code existence is not billability.
coverage E0650 returns
refuted, but the control codes E0601 and K0001 return the same, so this is a cache
limit and was correctly recorded as unconfirmed. L33829 was never read.
verified, so A50 The CMS DMEPOS fee schedule in force for… no longer rests on a failed claim. claim 117refuted is now refuted, and
IR-20 claim 117 came back refuted reviews that. This review's outcome stands for claims 23 and 96 only.
payment needs
data/hcpcs_payment_rates.csv, which holds the Clinical Lab Fee Schedule only. It caches one
schedule at a time, and no verified DMEPOS URL is recorded in data/README.md. No
allowable and no payment category was looked up in either direction. For 117, 42 CFR
414.229 is titled "capped rental items", but the 13-month wording was not reached in the
excerpt. Turn 2: Market Access has withdrawn the 13-month figure from its position
because nothing in this file reads it. The capped-rental category is its stated answer to
REQ-0121 Under the Medicare DMEPOS benefit (accepted). It was bound as claim 117refuted, then unconfirmed, and the chair will not mark
REQ-0121 Under the Medicare DMEPOS benefit answered on an unconfirmed claim. The COGS side of claim 96unconfirmed has no source because there is no bill of materials,
business case or volume. Operations states no figure.
neurogenic-orthostatic-hypotension.reimbursement.noh-payer-mix-age-distribution
(manifest, commercial-gap, filed by Commercial), REQ-0129 What share of idea-019's prescribed units… (market-access → commercial),
and REQ-0122 Does any US commercial payer or Medicare… (commercial → market-access, commercial and MA policy). Turn 2: Market
Access accepted REQ-0122 Does any US commercial payer or Medicare… and answered the MA half with claim 120verified: MA basic
benefits follow the Part B outcome. It has no tool for the commercial half and raised
REQ-0146 Retrieve the current medical/coverage… (research), which retrieves commercial and MA published coverage criteria. That
is now the commission against the commercial half of A21 Most US adults with symptomatic neurogenic…. For 33, REQ-0127 Will the pivotal study design generate…
(market-access → clinical) asks for a Medicare-inclusive pivotal cohort. Clinical's own
note is that NCT03482297's age cap of 80 should not be copied.
adoption
and market return unverifiable by design. What the Verifier did find bears on two of
them:
unconfirmed without primary research, and absorbing
them would decide that the demand side does not need settling before somebody funds the
supply side. REQ-0140 Specify the primary research that would… (front-end → commercial) asks Commercial to specify the instrument,
sample and decision rule for each. Commercial's own conditions already name the instruments:
a prescriber survey and a conjoint study. The fieldwork is a human spend decision. The
population leg of claim 24unconfirmed has its own open row for the missing PAF figure,
neurogenic-orthostatic-hypotension.epidemiology.paf-us-prevalence.
patent connector returns bibliographic dates only: no grant
status, claims, assignee or legal events. It confirms that the publication exists and is
live on a naive term to 2033-11-04 (claim 26verified). The filing-date discrepancy
(2013-11-04 at EPO (European Patent Office) against 2015-04-30 in claim 26verified) is unresolved. No landscape search has
been run by anyone (claim 27unconfirmed). Licence availability is in no record. Only
an enquiry to the rights holder settles it, and Legal classes that enquiry as a Tier 3
disclosure.
blocks absent that
licence. Unsearched art means the licence might not be enough.
abstains is the protocol working as intended: "I cannot answer from
what exists", with the work named. REQ-0110 Legal status and family of US2015313608 (legal status, family, granted claims,
assignee) and REQ-0111 A US patent landscape over… (CPC and assignee landscape), both legal-ip → research, are
open. So is REQ-0124 Does US2015313608 (commercial → legal-ip, whether the money model carries a royalty).
claim 43unconfirmed is commissioned against REQ-0110 Legal status and family of US2015313608 as its precondition, since there is no point
asking about a licence to a family with nothing granted. The enquiry itself is a human act.
clearance-summary K230028 as returning verified IFU text
on 2026-09-28. The Verifier's run of the same call the same day found no posted summary
(HTTP 401/404). Turn 2 re-run (2026-09-29): four runs retrieved the summary PDF. The
earlier miss was a transient fetch failure. The summary reads: "The system consists of
the controller, the tubing assemblies (provided with the controller) and single-patient
use garments (purchased separately from this controller)." The Verifier adds a caveat that
this review adopts. K230028 is a clinical-setting limb DVT-prophylaxis system. It
supports the architecture analogy only, not a predicate or an indication argument. The
tag stays unconfirmed on the design half alone.
unconfirmed for
one reason only: a window scan returns a ScanResult, which carries no tag, and no point
connector exists for a count. This is the shape of idea-001 IR-18 claim 90 came back unconfirmed.
abstains turns on REQ-0110 Legal status and family of US2015313608 and
REQ-0111 A US patent landscape over… (IR-15 claims 43), not on this claim, and Legal's "what would change my mind" names REQ-0110 Legal status and family of US2015313608
alone. What depended on claim 90unconfirmed is the question of what this developer could own, and
REQ-0112 Name, as concrete design elements, what… still answers that from the design side. The full-text read of the publication
will come with REQ-0110 Legal status and family of US2015313608 whether or not this row asks for it.
payment E0650,
payment E0651 and payment E0652 against data/dmepos_fee_schedule.csv. That file is
the CMS July 2026 DMEPOS fee schedule (dme26-c.zip), and its source is verified in
data/README.md. All three codes carry payment category IN (inexpensive and other
routinely purchased items) on every pricing line: NU, RR and UE. None is CR. The Verifier
read the raw CMS rows as well as the connector output (for example
E0650,RR,,D,IN,126.66,107.66,...), so this is not a parse artefact. The same file puts
the trunk appliance E0656 and the chest appliance E0657 in CR. E0656 is priced on an
RR line only, $82.35 non-rural (claim 107verified). The Verifier's notes on claims 23
and 96 record the purchase (NU) allowables from the same rows, non-rural, across the
contiguous states and DC: E0650 $872.43-$1,026.39, E0651 $1,112.52-$1,308.85, E0652
$6,422.01-$7,555.31. These are allowed amounts, and coinsurance comes out of them.
Is this refutation about our lookup rather than the world? I checked and it is not.
The raw rows were read, and the category field in the same file does discriminate: it
returns CR for E0656 and E0657, so an IN on the compressors is not an empty or default
field.
and claim 115unconfirmed`, and that choice alone is a factor of about
seven. The only recurring line left is replacement garments, claim 122unconfirmed.
So B7 It is a business. A stock-sized… now turns harder on claim 96unconfirmed (does COGS clear a one-time purchase allowable) and
claim 122unconfirmed (is there anything after it).
conditional on
C1-C6 together, and none of the other five moves with C3. Its budget paragraph ("the
cadence is not settled") now has an answer for the compressor family: one-off purchase,
or IN rental. The chair is not stale, because pivot: has not moved. But its C3 and its
stated REQ-0121 Under the Medicare DMEPOS benefit answer are contradicted, and REQ-0121 Under the Medicare DMEPOS benefit (accepted) is now answerable from
claims 107 and 117. That is the chair's re-statement to make, and no new request is
raised for it.
/refresh idea-019 rebuilds them. They
are not patched from here.
data/README.md). It is left open for the research lane to mark answered
against those claims. The front end does not answer a request addressed to another lane.
The subset of claims that are load-bearing, each with who depends on it and what breaks if it is false. Rows arrive two ways — the front end writes one, or a chair binds a condition to a claim, which is the definition of load-bearing.
If it is false: A cleared 510(k) or granted De Novo for automated abdominal compression treating OH exists. The De Novo launch route (device_class row 1) is then unavailable by definition — De Novo is only for devices with no predicate — and the device becomes a 510(k) follower to someone else's device; the "no cleared device alternative" limb of the indication rationale falls with it, and a competitor already holds the indication.
Depends on it: Regulatory, Commercial
If it is false: A granted De Novo for abdominal compression / orthostatic / splanchnic exists after all. Same break as A1 No FDA 510 on the De Novo half: the route in device_class row 1 closes and the first-to-De Novo position (the only non-IP moat Scores names) belongs to another sponsor.
Depends on it: Regulatory
If it is false: 21 CFR 870.5800 carries no non-limb product codes. The 510(k) repositioning route (device_class row 2) loses its only precedent for FDA reading a limb-sleeve regulation onto a non-limb compression device, and the candidate is De Novo-only — the second carried route is dead rather than open.
Depends on it: Regulatory
If it is false: PMID 27271310 did not show servo-controlled 40 mmHg splanchnic compression reducing orthostatic symptom burden in autonomic failure. The candidate then has no efficacy precedent at all for its mechanism in its population: indication-rationale (a) — a pivotal protocol written against a real prior cohort — has nothing under it, and the De Novo would be a first-in-human efficacy question.
Depends on it: Clinical & Scientific, Regulatory
If it is false: This device's bladder and servo loop do not reproduce the Vanderbilt binder's effect. A4 PMID 27271310's precedent then does not transfer, and the posture-triggered all-day shape has no efficacy basis of its own — claim 73verified already records that the precedent was manually activated for ≤10 minutes upright.
Depends on it: Clinical & Scientific (declared: C2), Technology & R&D
If it is false: Upright-only compression either does not raise standing BP via splanchnic unpooling, or does not give zero supine exposure in practice. The design property the whole differentiation trades on (compression only while upright, against pressor-drug supine hypertension) is gone, and the named failure modes are uncontrolled.
Depends on it: Clinical & Scientific, Regulatory
If it is false: A torso accelerometer/inclinometer cannot tell upright from recumbent in stooped or camptocormic PD/MSA patients at a safe false-inflation rate. The zero-supine-exposure safety case fails for exactly the MSA-P patients most likely to have supine hypertension (claims 82, 84); the indication must exclude them or the device must fall back to manual activation, which is not the P0 the original shape shape.
Depends on it: Technology & R&D, Regulatory (declared: C5), Clinical & Scientific (declared: C3)
If it is false: The device cannot be shown to vent to zero under single faults (pump runaway, sensor loss, posture-signal loss). The hazard analysis then carries an uncontrolled sustained-compression-while-recumbent failure in a population with 30-46% supine hypertension (claim 82verified), and no De Novo special control can be written around it.
Depends on it: Technology & R&D, Regulatory (declared: C4)
If it is false: Set pressure is not reached fast enough after a detected transition to blunt symptom onset. Posture triggering then adds nothing over manual pre-activation (claim 73verified), and the candidate's defining feature — the thing that separates it from a binder a patient inflates themselves — has no clinical purpose.
Depends on it: Technology & R&D, Clinical & Scientific
If it is false: Patients do not tolerate sustained 40 mmHg abdominal compression across every upright period. Real-world wear collapses to short bouts, the all-day use the intended use describes does not happen, and the tolerability on record (claims 57, 59, 74) is all study-day or low-pressure exposure that does not reach this question.
Depends on it: Clinical & Scientific, Commercial
If it is false: People with PD/MSA/PAF, with tremor, rigidity and impaired dexterity, cannot or will not don, charge and operate the garment daily. The DME purchase becomes a one-time sale to a non-user (claim 70unconfirmed records 43% never using stockings in an older OH cohort), the addressable share in A28 No competitor company was identified by the… loses its dexterity filter's population, and a coverage argument built on use fails on audit.
Depends on it: Commercial, Clinical & Scientific, Operations & NPI
If it is false: Patients do not perceive symptom relief in the first weeks. They abandon before any benefit accrues; claims 75 and 76 already record two binder studies with no symptom or real-life benefit, so there is no early-adherence precedent to lean on.
Depends on it: Commercial, Clinical & Scientific
If it is false: Neurologists and autonomic specialists will not prescribe a DME device in an indication managed with midodrine and droxidopa, or will not carry the DME documentation and prior-authorization burden. With no prescription there is no DME channel at all — the base case has no first step.
Depends on it: Commercial (declared: C4), Market Access
If it is false: Patients and prescribers treat "no supine pressure exposure" as a theoretical distinction. The device then competes with pharmacy-benefit pills on convenience alone, and the only differentiation the design rationale names does not change prescribing.
Depends on it: Commercial, Clinical & Scientific
If it is false: Midodrine and droxidopa are not the approved, pharmacy-benefit, supine-hypertension-labelled comparators this file says they are. The comparative argument in A6 Mechanism and clinical-risk reasoning and A14 Assumption then has nothing to be an advantage over, and the positioning against drug therapy must be rebuilt from the actual labels.
Depends on it: Commercial, Market Access, Clinical & Scientific
If it is false: CMS does not place a home-use, patient-owned abdominal compression device in the Part B DME benefit, or does not find it separately billable. The shape named in the title — "close on the existing prescription-DME benefit" — has no benefit to close on, and the base case has no Medicare payer.
Depends on it: Market Access, Commercial
If it is false: The E0650-E0652 pneumatic-compressor family and its trunk/chest appliance codes do not exist as described. There is no adjacent code family, the price anchor in A21 Most US adults with symptomatic neurogenic… has nothing to anchor to, and a new-code application becomes the only coding route rather than one of two.
Depends on it: Market Access
If it is false: CMS assigns no HCPCS code under which this device can be billed. No DMEPOS claim can be filed except under a miscellaneous code, which is the A25 TAM component 4 of 4 channel problem made permanent.
Depends on it: Market Access, Commercial
If it is false: No NCD or DME MAC LCD ever reaches automated abdominal compression for nOH. Medicare denies as not reasonable and necessary, NCD 280.6 (claim 9verified) stays the controlling text, and revenue is out-of-pocket only — the DME-benefit base case produces no Medicare revenue. What evidence a Medicare policy would accept is open as REQ-0147 What evidentiary standard does Medicare… (written LCD/NCD evidentiary standard).
Depends on it: Market Access, Clinical & Scientific
If it is false: The device's price and Medicare allowable do not sit in the E0650-E0652 purchase-allowable range. The TAM price leg has no anchor, and the DME unit economics (a purchase priced like a pneumatic compressor) is the wrong model for this device.
Depends on it: Commercial, Market Access, Operations & NPI
If it is false: Most prescribed patients are not Medicare beneficiaries. The Medicare DME coding and coverage strategy (A16 Assumption-A19 A Medicare national coverage determination…) then addresses a minority of units, and commercial-payer policy — unexamined in this file — becomes the route that matters. The Medicare Advantage (Medicare Advantage) half is covered by claim 120verified: MA basic benefits follow the Part B outcome. The commercial half is open as REQ-0146 Retrieve the current medical/coverage….
Depends on it: Market Access, Commercial (declared: C1)
If it is false: The pivotal cohort is not predominantly Medicare-aged (claims 6 and 7 record eligibility ranges straddling 65). The pivotal generates no Medicare-population outcomes, and the coverage argument in A19 A Medicare national coverage determination… needs a second study the calendar does not carry.
Depends on it: Clinical & Scientific, Market Access
If it is false: No DMEPOS supplier will stock, fit and bill the device without a device-specific code. There is no distribution channel between authorization and code assignment, so launch waits on A18 CMS will assign a HCPCS Level II code under… regardless of what FDA does.
Depends on it: Operations & NPI, Commercial
If it is false: The PD orthostatic-hypotension prevalence (33% pooled, 26% neurogenic, ~20% symptomatic) is not what the meta-analysis reports. The clinical-fraction leg of the TAM chain collapses and the population figure has no multiplier from PD prevalence to the indicated nOH population.
Depends on it: Commercial, Market Access
If it is false: The addressable share (symptomatic on non-pharmacologic measures, dextrous or supported, prescriber willing) is not a usable fraction of the nOH population. The TAM chain has population and no share, which is the state Scores already records — TAM stays blank as a core factor.
Depends on it: Commercial
If it is false: US2015313608 is not a real, live, on-mechanism family. There is then no IP to license, and the only defensibility route Scores names other than first-to-De Novo — licensed IP — does not exist.
Depends on it: Legal & IP, Commercial
If it is false: The Vanderbilt family is not available for exclusive license to a single developer. A live family (naive term to 2033-11-04) that reads on the core mechanism sits with a third party: FTO for the mechanism in the US is a problem until expiry, and the moat belongs to whoever holds the license.
Depends on it: Legal & IP (declared: C5), Commercial
If it is false: Another company is pursuing US authorization of a powered posture-triggered abdominal compression device (claim 60verified already records Isotech ISO-101 in a registered OH study). If they reach De Novo first, they create the predicate: this becomes a 510(k) follower (A1 No FDA 510) with no first-mover position.
Depends on it: Commercial (declared: C5), Regulatory
If it is false: A few stock sizes cannot deliver the set pressure across the body-habitus range. Per-patient custom manufacture follows, which is incompatible with a DME purchase priced at a pneumatic-compressor allowable (A20 TAM component 3 of 4) and with DMEPOS stock-and-fit (A23 A DMEPOS supplier will stock).
Depends on it: Operations & NPI (declared: C5), Technology & R&D
If it is false: Patients and families will not pay the out-of-pocket residual. Cash-pay is the one route to first revenue that does not wait on De Novo, a code and coverage in sequence (claim 42unconfirmed), and it has no payer. The Medicare route carries a 20% coinsurance that turns prescriptions into abandoned DME orders.
Depends on it: Commercial (declared: C3), Market Access
If it is false: A US member of the US2015313608 family has issued and is in force. A third party then holds an enforceable US right over the core mechanism until as late as 2033-11-04. US sale needs the licence in A27 The patent family published as US2015313608 or a design-around, and Legal states it would move toward blocks absent a licence.
Depends on it: Legal & IP (declared: C1)
If it is false: Live art outside the Vanderbilt family claims posture-triggered or servo-controlled abdominal compression for OH. Licensing the one named family (A27 The patent family published as US2015313608) then does not free the design, and FTO needs clearing against owners nobody has yet named. This is the loop's unstated proposition (2), now a claim.
Depends on it: Legal & IP (declared: C2)
If it is false: US2015313608 does not disclose posture-sensed activation. Legal's patentability map then changes in the device's favour: the trigger may become a candidate for this developer's own claims. No P0 the original shape element breaks in either direction, because P0 the original shape claims no IP in the trigger.
Depends on it: Legal & IP (declared: C3)
If it is false: JOW does not have 15 clearances from 14 applicants in two years. Legal's fast-follower reading of the hardware moat then overstates how crowded the field is. No P0 the original shape element breaks.
Depends on it: Legal & IP (declared: C4)
If it is false: The device is one integral unit, not controller plus garments plus charger. Then garment wear forces whole-unit replacement, per-patient cost multiplies, and the three-year DME expected-life condition (A62 This candidate's controller) cannot be met by a unit whose worn part is not separately replaceable.
Depends on it: Operations & NPI (declared: C1), Market Access (declared in its 2026-09-29 position as the premise of its C5, claim 119unconfirmed; a stated dependency, not a bound condition)
If it is false: The garment is not in the surface / intact-skin / permanent-contact category with those endpoints. The biocompatibility plan is then mis-sized in one direction or the other, and the laundering regimen may not have to be fixed before testing. That is a schedule and cost change to the garment programme, not a shape change.
Depends on it: Operations & NPI (declared: C2)
If it is false: FDA would not expect IEC 60601-1, -1-2, -1-11, IEC 62304 and IEC 62133-2 conformance. The third-party test campaign, which is unscheduled and uncosted, is then a different campaign, and Operations' pilot plan and cost structure are drawn against the wrong list.
Depends on it: Operations & NPI (declared: C3), Regulatory
If it is false: The JOW 2021-2026 recall census is not four records with those root causes. Operations' two process lessons (firmware change control on the pressure logic; SKU labelling and packaging control) then lose their named analog. No P0 the original shape element breaks: both disciplines are standard for a software-controlled pressure device in any case.
Depends on it: Operations & NPI (declared: C4)
If it is false: Fully loaded per-patient COGS is above the E0650-family allowable at the business case's volume, or at a tenth of it. Every unit sold under the only named payment then loses money, and the P0 the original shape unit economics fail. This is the loop's unstated proposition (3), now a claim.
Depends on it: Operations & NPI (declared: C6), Commercial
If it is false: A pump, vent valve or pressure sensor the controller needs is single-source. Supply continuity then rests on one vendor, and any forced substitution becomes a design change under FDA change control. That is the recall class in A38 openFDA device recalls for product code JOW….
Depends on it: Operations & NPI (declared: C7), Technology & R&D
If it is false: NCT03482297 has no positive result. The only controlled evidence for this mechanism class is then single-blind (claim 5verified). Clinical states it would move to blocks on the symptom claim and ask for a BP/tolerance-only indication, and the De Novo symptom claim loses its nearest precedent.
Depends on it: Clinical & Scientific (declared: C1), Regulatory
If it is false: Sustained home wear fails: compression is active for less than most upright time, or one in five or more discontinue for discomfort. The all-day intended use does not happen, the pivotal has no variance estimate to be sized on, and a DME purchase goes to a non-user (A11 Assumption).
Depends on it: Clinical & Scientific (declared: C4), Commercial, Market Access
If it is false: The 12-week sham-controlled pivotal does not beat sham on OHQ composite by at least droxidopa's margin. There is then no symptom-burden claim to authorise. The De Novo intended use falls back to a haemodynamic claim at best (Regulatory's lever 3), and the coverage argument in A19 A Medicare national coverage determination… has no outcome to rest on. Whether an OHQ primary could carry a coverage policy at all is open as REQ-0147 What evidentiary standard does Medicare… (Market Access's answer route for REQ-0134 Would a DME MAC local coverage determination).
Depends on it: Clinical & Scientific (declared: C5), Regulatory, Market Access
If it is false: The effect is absent or materially smaller in Parkinson disease. The largest population in the indication then has no powered-device evidence, the indication narrows to MSA/PAF (Clinical's named pivot), and the TAM chain loses its PD leg (claims 22, 81).
Depends on it: Clinical & Scientific (declared: C6), Commercial
If it is false: FDA classifies the device Class III. PMA replaces De Novo, and the evidence burden, calendar and capital the P0 the original shape shape assumes do not fit. This is the Regulatory half of the loop's unstated proposition (1), now a claim.
Depends on it: Regulatory (declared: C1), Commercial
If it is false: An anti-shock trouser 510(k) under 870.5800 carries an OH or home-use indication. A predicate then exists: device_class row 1 (De Novo) is likely unavailable, and the "no cleared alternative" limb and the first-to-De Novo position fall. This is the same break as A1 No FDA 510, reached from a different record.
Depends on it: Regulatory (declared: C2), Commercial, Market Access
If it is false: FDA has not cleared truncal pneumatic compression under 870.5800. The 510(k) route (device_class row 2) then loses its anatomy precedent and rests on the limb text alone.
Depends on it: Regulatory (declared: C3)
If it is false: A powered abdominal garment with no OH claim could sit in Class I after all. The fallback in device_class row 3 is then as the candidate file already states it, and Regulatory's correction of that row does not hold. No P0 the original shape launch route uses row 3.
Depends on it: Regulatory (declared: C6), Operations & NPI, Commercial
If it is false: FDA would not accept an NCT03482297-design sham RCT in posture-triggered home mode as De Novo clinical data. The pivotal in A43 A randomized is then the wrong study, and the clinical package, calendar and capital all grow by an amount nobody has estimated.
Depends on it: Regulatory (declared: C7), Clinical & Scientific
If it is false: The 2026 DMEPOS fee schedule publishes no national allowable for E0650-E0652 and E0656, for example because they are locally priced. claim 23unconfirmed's price anchor then has no published figure, the TAM price leg stays blank, and A39 At the annual production volume idea-019's… has no denominator.
Depends on it: Commercial (declared: C2), Market Access, Operations & NPI
If it is false: A single-torso-sensor classifier cannot reach under 1 in 1,000 false-upright recumbent periods, lasting no more than 60 s, in PD/MSA/PAF including camptocormia and dyskinesia. Posture-triggered inflation then cannot carry a safety case in the indicated population. The P0 the original shape defining feature needs an MSA-P / deformity exclusion or manual activation, which three chairs name as their pivot.
Depends on it: Technology & R&D (declared: C1), Regulatory, Clinical & Scientific
If it is false: A wearable unit cannot reach 90% of 40 mmHg within 15 s of detected standing. Compression then arrives after the symptomatic fall, posture triggering adds nothing over manual pre-activation (A9 A posture-triggered abdominal compression…), or the pneumatics grow to a reservoir that costs size and noise.
Depends on it: Technology & R&D (declared: C2), Clinical & Scientific, Operations & NPI
If it is false: The bench rig does not vent below 5 mmHg within 10 s under each single fault through a firmware-independent path. This is A8 A bench rig can demonstrate that the device…'s break with numbers on it: no special control can be written around sustained recumbent compression.
Depends on it: Technology & R&D (declared: C3), Regulatory, Operations & NPI
If it is false: No independent recumbency interlock bounds a false inflation at 60 s. The "bounded, with independent interlock" safety case Technology offers in place of "zero by construction" then has no second line, and supine exposure is bounded only by the primary classifier (A51 A posture classifier running on a single…).
Depends on it: Technology & R&D (declared: C4), Regulatory, Clinical & Scientific
If it is false: In three stock sizes, interface pressure does not stay within 5 mmHg of set pressure across habitus. This is A29 A garment platform in a small number of…'s break measured at the skin: custom fit, or a delivered dose that varies with the patient.
Depends on it: Technology & R&D (declared: C5), Operations & NPI
If it is false: The classifier's decision shifts when its own bladder inflates or vents, or as the housing migrates. The actuator then corrupts its own trigger, false vents and false inflations are correlated with the device's own action, and Technology names this the integration failure.
Depends on it: Technology & R&D (declared: C6), Regulatory
If it is false: A battery of 20 Wh or less cannot run a 16-hour posture-triggered day. The result is a mid-day recharge or a larger pack, and daily use by patients with impaired dexterity (A11 Assumption) gets harder. Costly, not a shape change.
Depends on it: Technology & R&D (declared: C7), Operations & NPI, Commercial
If it is false: An existing E0650-E0676 descriptor does fit this device. Market Access's reading that a new code is the realistic route (and that FDA authorisation must precede the coding application) is then wrong in the device's favour, and A18 CMS will assign a HCPCS Level II code under… gets shorter.
Depends on it: Market Access (declared: C1)
If it is false: NCD 280.6's own device description does reach an abdominal sustained-pressure garment. The device is then under an NCD that excludes nOH (A19 A Medicare national coverage determination…), and RAPID's controlling-NCD exclusion (claim 13verified) bites.
Depends on it: Market Access (declared: C2)
If it is false: This row matters in both directions. If E0650-E0652 are not capped rental, Market Access's reading of the cadence is wrong. If they are, the "purchase allowable" in claim 23unconfirmed and A20 TAM component 3 of 4 describes a payment Medicare does not make: revenue is a use-contingent capped-term rental, and the controller is a supplier-carried fleet asset. The length of the term is written into claim 117refuted but was not found in the 414.229 excerpt the Verifier read, and Market Access no longer states it as a number. Turn 3 (2026-09-29): refuted in the first direction. Reviewed in IR-20 claim 117 came back refuted (absorb).
Depends on it: Market Access (declared: C3), Commercial, Operations & NPI
If it is false: L33829 is not limb/lymphedema/CVI-only, or is not in effect. The coverage leg then has a DME MAC route other than a new NCD or LCD request, in the device's favour. Market Access's statement that the coverage leg rests entirely on a new policy would not hold.
Depends on it: Market Access (declared: C4)
If it is false: The controller is not built for repeated use by successive patients and a life of at least three years. It then fails 42 CFR 414.202 conditions (1)-(2) and is not DME at all. The shape named in the title, closing on the Part B DME benefit, has no benefit to close on (A16 Assumption).
Depends on it: Market Access (declared: C5), Technology & R&D
If it is false: MA plans are not bound by Traditional Medicare's NCDs and benefit-category conditions. The Part B DME outcome then does not govern MA enrollees, and payer mix (A21 Most US adults with symptomatic neurogenic…) splits into a second policy question.
Depends on it: Market Access (declared: C6), Commercial
Any department may ask any other what it cannot answer itself. The answer must name an artifact that exists — a research report, a position, a dossier — never a summary.
| Request | From → to | Question | State |
|---|---|---|---|
| REQ-0110 | legal-ip → research | Legal status and family of US2015313608 ('Compression device, system, and method for decreasing abdominal venous pooling', filed 2013-11-04): retrieve the INPADOC family and the OPS /legal events (or USPTO (United States Patent and Trademark Office) Patent Center file history) for every US member, and… | open |
| REQ-0111 | legal-ip → research | A US patent landscape over posture-triggered and servo-controlled abdominal/truncal compression for orthostatic hypotension, run by CPC class and keyword (not by patent number), in the same form REQ-0002 A patent landscape over closed-loop… used for idea-001: ad-hoc CQL against EPO OPS… | open |
| REQ-0112 | legal-ip → technology | Name, as concrete design elements, what this candidate's implementation would do that the Vanderbilt servo-controlled binder (PMID 27271310, claim 5verified, claim 73verified), the published US2015313608 application, and the motor-driven posture-triggered binder in PMID… | open |
| REQ-0113 | operations-npi → technology | For the idea-019 controller: what are the bladder's inflated volume at 40 mmHg, the required rise time to set pressure (claim 45unconfirmed), the expected daily upright duty cycle per charge, and is the vent-to-zero single-fault function (claim 49unconfirmed) implemented by a… | open |
| REQ-0114 | operations-npi → commercial | What unit does the idea-019 money model sell and at what volume: the controller's price and whether it is a purchase or rental, the garment replacement cadence and who pays for replacements, and the annual system volume assumed in year 1 and year 3? | open |
| REQ-0115 | operations-npi → market-access | Under the E0650-E0652 family, are replacement garments or appliances (including the trunk/chest appliance codes claim 10unconfirmed names) separately billable to Medicare on a replacement schedule, or would a one-time purchase allowable have to cover a patient's… | accepted |
| REQ-0116 | technology → clinical | In adults with neurogenic orthostatic hypotension due to primary autonomic failure, how many seconds after assuming an upright posture does the symptomatic systolic fall begin, so that a posture-triggered device must reach set pressure before it? Technology's… | open |
| REQ-0117 | technology → clinical | If supine exposure to 40 mmHg abdominal compression is bounded rather than zero (false-inflation events vented by an independent interlock within 60 s, Technology condition C4), is that exposure clinically harmless in a population with 30-46% supine… | open |
| REQ-0118 | technology → regulatory | Would FDA review of a De Novo safety case for this device accept a hazard analysis in which supine compression exposure is bounded by an independent, firmware-separate recumbency interlock and a de-energise-to-vent valve (Technology conditions C3 and C4)… | open |
| REQ-0119 | technology → research | Literature pass: what false-upright (lying or sitting classified as standing) and missed-standing rates have been reported for single trunk- or lower-back-worn inertial sensors in Parkinson disease, MSA or older adults, broken out for dyskinesia and… | open |
| REQ-0120 | technology → research | Full-text read: what bladder dimensions, inflated volume at ~40 mmHg, pump flow and battery are reported for the Vanderbilt servo-controlled abdominal binder (PMID 27271310, PMC4945429; NIH award 5R01HL144568), and what bladder-to-skin interface pressure… | open |
| REQ-0121 | commercial → market-access | Under the Medicare DMEPOS benefit, what payment category do HCPCS E0650-E0652 fall in (inexpensive/routinely purchased, capped rental, or other), and are the pneumatic appliance codes (e.g. E0656, trunk) separately payable on replacement at a stated interval?… | accepted |
| REQ-0122 | commercial → market-access | Does any US commercial payer or Medicare Advantage medical policy on pneumatic compression devices or abdominal binders name orthostatic hypotension (neurogenic or otherwise) as a covered indication, or expressly exclude it? | accepted |
| REQ-0123 | commercial → operations-npi | What is the expected unit cost of goods, at pilot and at first-scale volume, for the P0 the original shape device as the mechanism describes it (battery pump, posture sensor, servo pressure control, inflatable abdominal bladder garment in stock sizes), and what share of it is… | open |
| REQ-0124 | commercial → legal-ip | Does US2015313608 (Vanderbilt, filed 2013-11-04, naive expiry 2033-11-04) have granted claims that read on posture-triggered servo-controlled abdominal compression as the P0 the original shape mechanism describes it, such that a US seller would need a licence before expiry? | open |
| REQ-0125 | market-access → research | Full-text retrieval of DME MAC LCD L33829 'Pneumatic Compression Devices' and its companion policy/billing article (the coverage cache fetched 2026-09-28 carries only A59219, a Response to Comments on DL33829, and no code rows for E0650-E0676): record… | open |
| REQ-0126 | market-access → regulatory | Which classification outcome does Regulatory expect for idea-019 — a 510(k) to 21 CFR 870.5800 / JOW (device_class row 2) or a De Novo creating a new classification regulation (row 1) — and, under the De Novo, would the identification text describe a device… | open |
| REQ-0127 | market-access → clinical | Will the pivotal study design generate home-use outcomes — orthostatic symptom burden and upright time — over a sustained period (state the duration) in a cohort that includes Medicare beneficiaries, rather than study-day or laboratory tilt outcomes only… | open |
| REQ-0128 | market-access → technology | Is the idea-019 controller (pump, valve, posture sensor, battery) specified for an expected life of at least three years and for reissue to successive patients, and what is the expected service life of the garment/bladder? | open |
| REQ-0129 | market-access → commercial | What share of idea-019's prescribed units does Commercial expect to fall in Medicare fee-for-service, Medicare Advantage, commercial insurance, Medicaid/VA and cash pay? | open |
| REQ-0130 | regulatory → technology | Does the P0 the original shape architecture vent the abdominal bladder to zero on power loss, controller fault, pressure-sensor failure or posture-signal loss through a path that does not depend on the software control loop (e.g. a normally-open valve), and within what time? | open |
| REQ-0131 | regulatory → clinical | What pivotal design (population, sham control, primary endpoint, duration, approximate size) would demonstrate a symptom-burden and upright-standing-time benefit for posture-triggered, home-use abdominal compression, given the only efficacy precedent was… | open |
| REQ-0132 | clinical → regulatory | Would FDA accept, as the pivotal clinical evidence for a De Novo authorizing a neurogenic-orthostatic-hypotension symptom claim for this device, a randomized double-blind parallel-group study against the same device inflating to a ~5 mmHg sham (the… | open |
| REQ-0133 | clinical → technology | Can the device record, with timestamps, its posture classification state and bladder pressure, retained on-device or uploaded, at a resolution sufficient to serve as objective study endpoints for (a) device-detected upright time, (b) compression-active time… | open |
| REQ-0134 | clinical → market-access | Would a DME MAC local coverage determination (or an NCD reconsideration of NCD 280.6) reach automated abdominal compression for symptomatic nOH on a pivotal whose primary endpoint is a symptom score (OHQ composite at 12 weeks), or would coverage require a… | accepted |
| REQ-0135 | front-end → research | Is there any FDA 510(k) or De Novo whose indication is treating orthostatic hypotension (or countering hypotension) with an external compression garment? Two parts. (a) An indication-level search, not a device-name search: 510(k) summary/statement text and De… | open |
| REQ-0136 | front-end → research | Who else is developing a powered, posture-triggered or automated abdominal compression device for orthostatic hypotension toward US authorisation? Start from Isotech Ltd ISO-101 (NCT06039410, claim 60verified): what the device does, its regulatory status, and the… | open |
| REQ-0137 | front-end → research | Has any result of NCT03482297 (Vanderbilt; automated abdominal binder at about 40 mmHg vs a 5 mmHg sham; MSA and PAF; COMPLETED; hasResults=false on the registry as of 2026-09-28) been published or presented? Search PubMed by NCT number and by investigator… | open |
| REQ-0138 | front-end → research | What do the current FDA labels for midodrine hydrochloride and droxidopa (Northera) say about (a) the approved indication wording, (b) supine hypertension (boxed warning or otherwise), and (c) the durability-of-effect statements that claims 61 and 62 carry?… | open |
| REQ-0139 | front-end → research | Find the CMS DMEPOS fee schedule file in force for 2026 (the quarterly DMEPOS public use file). Record its URL and release so it can be added to data/README.md as a verified source. Then report, for E0650, E0651, E0652, E0656 and E0657, the payment-category… | open |
| REQ-0140 | front-end → commercial | Specify the primary research that would settle idea-019's stakeholder-future claims. They are: prescriber willingness to prescribe the device and carry the DME and prior-authorisation burden (claim 29unconfirmed); whether 'no supine exposure' changes prescribing (claim… | open |
| REQ-0141 | front-end → clinical | Can the home-use feasibility study in your C4 (claim 99unconfirmed) pre-specify endpoints that also settle claims 28, 38 and 39? (a) The proportion who don, charge and operate the device independently or with caregiver help at week 4 (claim 28unconfirmed). (b) Patient-perceived… | open |
| REQ-0142 | front-end → regulatory | Draft the Pre-Submission (Q-Sub) question set a human would file for idea-019. Cover: (a) classification, i.e. De Novo Class II with special controls, Class III, or 510(k) under 870.5800, for this intended use (claim 102unconfirmed; REQ-0126 Which classification outcome does…); (b) whether Clinical's C5… | open |
| REQ-0143 | front-end → regulatory | Under FDA's current guidance on ISO 10993-1, which contact category and duration apply to idea-019's garment? Operations C2 states: surface device, intact skin, cumulative contact over 30 days. Which biocompatibility endpoints apply? Does the guidance's… | open |
| REQ-0144 | front-end → market-access | Your position binds conditions C1-C6 to claims 88-93. Those claims carry Legal & IP C1-C4 (88-91) and Operations & NPI C1-C2 (92-93). The claims appended from your conditions are 115-120: their source field reads 'condition C1..C6 from the market-access… | answered |
| REQ-0145 | front-end → research | Bring into Claims, as unverified, two items that Clinical & Scientific found and asked the front end to route. (1) PMID 31109911 (SENATOR ONTOP, a review of systematic reviews in older people with OH, searched to June 2018): abdominal compression reduced the… | open |
| REQ-0146 | market-access → research | Retrieve the current medical/coverage policies on pneumatic compression devices (and on abdominal binders or compression garments, where a separate policy exists) of the largest US commercial health plans and of the largest Medicare Advantage organisations'… | open |
| REQ-0147 | market-access → research | What evidentiary standard does Medicare apply when a DME MAC writes or reconsiders an LCD, or CMS opens or reconsiders an NCD, for a symptom-treating DME item? Retrieve verbatim: (a) the reasonable-and-necessary and evidence provisions of Medicare Program… | open |
python3 engine/scripts/check_loop.py --candidate idea-019 --open
Nothing on this page is a recommendation, and no verdict here is a decision. This is a compilation of what the loop record, the position files and the request ledger say. Shortlist review and every decision past it are human-only.
_shared/plain-language.md